Literature DB >> 15678503

Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.

Yuzhuo Wang1, Monica P Revelo, Daniel Sudilovsky, Mei Cao, Wilfred G Chen, Lester Goetz, Hui Xue, Marianne Sadar, Scott B Shappell, Gerald R Cunha, Simon W Hayward.   

Abstract

BACKGROUND: Various research groups have attempted to grow fresh, histologically intact human prostate cancer tissues in immunodeficient mice. Unfortunately, grafting of such tissues to the sub-cutaneous compartment was found to be associated with low engraftment rates. Furthermore, xenografts could only be established using high-grade, advanced stage, but not low- or moderate-grade prostate cancer tissues.
METHODS: This paper describes methods for xenografting both benign and malignant human prostate tissue to severe combined immunodeficient (SCID) mice. We examine the efficiency and histopathologic consequences of grafting to the sub-cutaneous, sub-renal capsule, and prostatic orthotopic sites.
RESULTS: Sub-renal capsule grafting was most efficient in terms of take rate (>90%) for both benign and malignant tissue. Orthotopic grafts consistently exhibited the best histopathologic differentiation, although good differentiation with continued expression of androgen receptors (AR) and PSA was also seen in the sub-renal capsule site. Sub-cutaneous grafting resulted in low take rates and the lowest level of histodifferentiation in surviving grafts. Grafted benign tissues in all sites appropriately expressed AR, PSA, cytokeratins 8, 18, and 14 as well as p63; carcinoma tissues did not express the basal cell markers. Grafting of tissues to castrated hosts did not affect the graft take rates (but was not practical in the case of the orthotopic site). Grafting followed by host castration resulted in epithelial regression with loss PSA and reduced AR expression at all three sites.
CONCLUSIONS: These data suggest that sub-renal capsule and orthotopic grafting of human prostate tissue can be used for many basic scientific and translational studies. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15678503     DOI: 10.1002/pros.20225

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  74 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

2.  Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia.

Authors:  Tristan M Nicholson; Kristen S Uchtmann; Conrad D Valdez; Ashleigh B Theberge; Tihomir Miralem; William A Ricke
Journal:  J Vis Exp       Date:  2013-08-28       Impact factor: 1.355

3.  Tissue slice grafts: an in vivo model of human prostate androgen signaling.

Authors:  Hongjuan Zhao; Rosalie Nolley; Zuxiong Chen; Donna M Peehl
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

4.  Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts.

Authors:  Donald J Vander Griend; Yuko Konishi; Angelo M De Marzo; John T Isaacs; Alan K Meeker
Journal:  Prostate       Date:  2009-10-01       Impact factor: 4.104

Review 5.  Gene targeting to the stroma of the prostate and bone.

Authors:  Roger S Jackson; Omar E Franco; Neil A Bhowmick
Journal:  Differentiation       Date:  2008-05-20       Impact factor: 3.880

6.  Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Authors:  Chiara Grisanzio; Apryle Seeley; Michelle Chang; Michael Collins; Arianna Di Napoli; Su-Chun Cheng; Andrew Percy; Rameen Beroukhim; Sabina Signoretti
Journal:  J Pathol       Date:  2011-06-27       Impact factor: 7.996

Review 7.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

8.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Authors:  Hongwei Cheng; Paul W Clarkson; Dongxia Gao; Marina Pacheco; Yuzhuo Wang; Torsten O Nielsen
Journal:  Sarcoma       Date:  2010-10-13

Review 10.  Human benign prostatic hyperplasia heterotransplants as an experimental model.

Authors:  Lluis-A Lopez-Barcons
Journal:  Asian J Androl       Date:  2009-11-30       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.